ABT.NEO Abbott Labs CDR (CAD Hedged)

Healthcare Medical Devices NEO Exchange
18.52 CAD
Close of Oct 30, 2026
14.36 22.76
Market cap
CAD 244B
P/E
13.1x
P/B
3.38x
ROE
8.3%
Dividend yield
1.58%
Fundamental score
2.0/5

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2026.

Is ABT.NEO undervalued?

Graham number
Price18.52
Graham value13.19
Premium40.4%

ABT.NEO trades 40.4% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Abbott Labs CDR (CAD Hedged) fundamental analysis

11 of 22 checks passed

ROE 0/2

Low return on equity (8.3%), below 10%.

ROA 1/1

Return on assets (3.9%) is above the industry median (-7.4%).

Profit Consistency 1/2

Profitable for 4 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share history is shorter than 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 0/1

Last year's EPS growth (-51.5%) is below the industry median (5.2%).

Revenue Growth 1/2

Revenue grew 0.5% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 0/1

Current assets do not cover long-term liabilities.

Debt to Equity 1/2

Moderate debt to equity (56.9%), up to 100%.

Debt Trend 0/1

Debt to equity history is shorter than 5 years.

Debt Coverage 0/1

Operating cash flow does not cover 20% of total debt.

Interest Coverage 1/1

EBIT is 9.3x against interest expense, well covered.

PE vs Market 1/1

PE (12.9x) is below the market median (20.3x).

PE vs Industry 1/1

PE (12.9x) is below the industry median (19.0x).

PBV 0/1

Price to book (3.3x) is above the industry median (2.5x).

Graham Number 0/1

The price is above the Graham number (PE x PB = 43.0, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 1/2

Dividend yield (4.9%) is above the bottom 25% of dividend payers in the market.

Dividend Stability 1/2

Dividends paid without a cut of more than 10% for 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 1/1

Payout ratio is 63.1%, covered by earnings.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Abbott Labs CDR (CAD Hedged) stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Abbott Labs CDR (CAD Hedged)

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, h…

Full company profile